Ascletis Pharma Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jinzi Jason Wu
- Full Time Employees
- 231
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building D Hangzhou People's Republic of China
- IPO Date
- Nov 19, 2019
- Website
- ascletis.com
- Similar Companies
- Business
- Ascletis Pharma Inc. (HKEX: 1672) is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics for metabolic diseases, infectious diseases, cancer lipid metabolism, and viral hepatitis. Founded in 2013 and headquartered in Hangzhou, Zhejiang Province, People's Republic of China, the company utilizes proprietary technologies including Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT) to advance its pipeline; core marketed products include ritonavir tablets, GANOVO (danoprevir) for hepatitis C, and ASCLEVIR (daclatasvir) for hepatitis C, while its R&D portfolio features ASC30, a small molecule GLP-1R agonist for oral daily or subcutaneous monthly-to-quarterly dosing in chronic weight management; ASC35, a once-monthly subcutaneous GLP-1R/GIPR dual peptide agonist for obesity and metabolic diseases; ASC36, a once-monthly subcutaneous amylin receptor peptide agonist; ASC37, an oral GLP-1R/GIPR/GCGR triple peptide agonist; ASC40 for recurrent glioblastoma and acne; ASC42 for primary biliary cholangitis; ASC22 for HBV functional cure; ASC61 for advanced solid tumors; and others targeting NASH, HIV, respiratory syncytial virus, and cancer lipid metabolism via FASN inhibitors like denifanstat. Ascletis primarily serves patients in China and pursues global markets through U.S. FDA IND submissions, with recent advancements including the selection of ASC35 in October 2025 as a best-in-class once-monthly obesity candidate with planned FDA IND in Q2 2026, ASC37 in November 2025 as its first oral incretin triple agonist using POTENT technology with FDA IND targeted for Q2 2026, positive topline Phase Ib results for ASC30 supporting quarterly dosing in obesity, completion of a share placing in August 2025 raising net proceeds for R&D, and topline data expected in Q1 2026 for ongoing trials. The company operates through subsidiaries like Gannex for NASH therapies and maintains a pipeline of 17 to 22 candidates, with eleven developed in-house.
Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)
Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions
Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes
Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes
Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development
Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025
Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development
Ascletis to Present Study Results of ASC30 Oral Tablet, ASC30 Injection, and Combination of ASC31 and ASC47 at ObesityWeek® 2025
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
Ascletis Selects a Best-In-Class Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for Clinical Development
Ascletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide Monotherapy
Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025